Warfarin had long been considered the gold standard for anti-coagulation (blood thinning), although the stringent monitoring of diet and blood levels had both patients and their caregivers pining for something easier. Various factors needed to be considered in order to achieve a fine line between blood thinning that was deemed sufficient for the patient, v. thinning the blood too much and risking bleeding events or serious hemorrhaging.
While no caregiver or healthcare provider would knowingly put a patient at risk, at the same time the medical community had long been hoping for a breakthrough that would see the introduction of a drug equal to warfarin’s effectiveness, with less hassle.
One of two new drugs to be introduced in recent years is Xarelto, hailed as the kind of breakthrough patients and their caregivers were seeking: a blood thinner equal to warfarin’s effectiveness, but without the need for stringent monitoring – or so the manufacturer claimed.
Rivaroxaban however turned out to be anything but a savior: Xarelto bleeding events occurred in some patients (as they do with warfarin). The big difference, however, turned out to be the lack of a reversing agent in the new product that doctors had been able to employ in their Coumadin patients to quickly reverse the thinning properties of warfarin and allow the blood to once again coagulate more quickly, in order to stop a hemorrhage.
While an antidote for Xarelto has now, reportedly been found and is being tested, it wasn’t available at the time Xarelto came to market.
It is against this backdrop of litigation that Alere recalled its INRatio measuring devices last July, casting some doubt on the accuracy and validity of data used to determine the effectiveness of Xarelto (rivaroxaban) for the treatment of non-valvular atrial fibrillation when compared with Coumadin (warfarin).
The INRatio device, manufactured by Alere, was used to monitor warfarin therapy in the control group enrolled in the ROCKET-AF trial. However, the readings of the INRatio device were called into question, with subsequent concerns that Coumadin control group patients may have received more warfarin than they otherwise would have been given had the INRatio readings been accurate beyond any doubt.
READ MORE ALERE INRATIO RECALL LEGAL NEWS
Alere recalled the INRatio device in July of 2016. Since then the FDA, in October, made a determination there were no significant impacts, and that “effects on strokes or bleeding, including bleeding in the head, were minimal.”
That didn’t stop a slide in the performance of Alere, which in turn has spooked Abbott Laboratories Inc. and is attempting to back out of a proposed merger with Alere. The consolidated cases are Alere Inc. v. Abbott Laboratories Inc., Case No. 12691, Abbott Laboratories v. Alere Inc., Case No. 12872, and Abbott Laboratories Inc. v. Alere Inc., Case No. 12963, all in the Court of Chancery of the State of Delaware.
Trial is not expected until sometime in April.